此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Palbociclib 组合在 HR+HER2-MBC 中的治疗模式和临床结果 (PRECIOUS)

2026年6月9日 更新者:Pfizer

Palbociclib 联合治疗 HR+/HER2- 转移性乳腺癌患者:一项关于非洲中东地区治疗模式和临床结果的非干预性前瞻性研究(PRECIOUS)

这项非干预性多中心研究的目的是提供关于开始使用 palbociclib 联合治疗的患者的前瞻性观察数据,以有助于了解 HR+ HER2-转移性/局部晚期乳腺癌 (BC) 疾病管理、治疗模式、临床结果和生活质量 (QoL) 在非洲和中东国家的常规临床实践中。

研究概览

地位

完全的

详细说明

HR+/HER2- 转移性/局部晚期 BC 患者的主治医师已做出使用 palbociclib 的治疗决定且符合资格标准的患者将被邀请参加该研究。 根据许可的适应症开始使用 palbociclib 加来曲唑/芳香酶抑制剂或 palbociclib 加氟维司群治疗的患者,作为入组时转移性/局部晚期 BC 的一线或二线治疗,可纳入研究。

本研究中评估的变量将包括患者人口统计学、临床特征、合并症和合并用药、HR+ HER2-局部晚期和转移性 BC 治疗史、当前 BC 治疗、体能状态(东部肿瘤合作组 (ECOG))、临床结果和生活质量。 本协议中描述的所有评估都是作为正常临床实践或标准实践指南的一部分进行的,适用于正在进行这项非干预性研究的国家的患者群​​体和医疗保健提供者专业。 本研究中收集的所有数据旨在捕捉 HR+/HER2- 转移性/局部晚期 BC 患者的真实世界治疗模式和结果。 电子病例报告表 (eCRF) 将用于数据收集。 调查人员将在协议、电子数据采集 (EDC) 系统(即 eCRF)、调查现场主文件 (ISMF)、文档和任何适用的研究流程方面接受初步现场访问的培训。 任何与这项非干预性研究 (NIS) 的执行相关的新信息都将在研究期间转发给医务人员。 将在研究期间进行远程数据监测,以确保及时报告安全数据、数据完整性和一致性。

研究类型

观察性的

注册 (实际的)

185

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Doha、卡塔尔
        • Hamad Medical Corporation
      • Alexandria、埃及
        • Alexandria School of Medicine/Clinical Research Center CRC
      • Cairo、埃及、11796
        • National Cancer Institute
      • Cairo、埃及
        • Ain Shams University Hospital
      • Cairo、埃及、11745
        • Dar El Salam Oncology Hospital
      • Dammam、沙特阿拉伯
        • King Fahad Specialist Hospital KFSH-Dammam
      • Riyadh、沙特阿拉伯
        • National Guard Hospital, Riyadh
      • Amman、约旦、11941
        • King Hussein Cancer Center
      • Beirut、黎巴嫩
        • American University of Beirut Medical Center
      • Beirut、黎巴嫩
        • Hôtel Dieu de France (HDF)
      • Jdeidé - Metn、黎巴嫩
        • Saint Joseph Hospital - Cancer Centers of Colorado
      • Sidon、黎巴嫩
        • Hammoud Hospital University Medical Center (HHUMC)

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 90年 (成人、年长者)

接受健康志愿者

不

取样方法

非概率样本

研究人群

HR+/HER2- 转移性/局部晚期乳腺癌患者

描述

纳入标准:

  1. ≥ 18 岁或以上,诊断为乳腺腺癌,有转移性/局部晚期疾病的证据,不适合治愈性治疗。
  2. 根据当地标准记录的 HR+(ER+ 和/或 PR+)肿瘤
  3. 根据当地标准记录的 HER2- 肿瘤
  4. 将根据许可适应症开始使用 palbociclib 加来曲唑/芳香酶抑制剂或 palbociclib 加氟维司群治疗,作为入组时转移性/局部晚期 BC 的一线或二线治疗
  5. 研究者认为愿意并能够遵守定期门诊就诊的患者
  6. 个人签署并注明日期的知情同意书的证据,表明患者(或法律上可接受的代表)已被告知研究的所有相关方面

排除标准:

  1. 参加任何介入临床试验的患者
  2. 在入组时接受除转移性/局部晚期 BC 以外的恶性肿瘤积极治疗的患者
  3. 无法理解研究性质且不愿签署知情同意书的患者

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:队列
  • 时间观点:预期

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Percentage of Participants Who Were Progression Free at 6 Months Post Palbociclib Initiation
大体时间:At 6 months from the date of palbociclib initiation in routine clinical practice
Percentage of participants who were progression free was defined as percentage of participants who were alive and for whom no progression of disease was reported. Progression of disease was defined as an increase in visible disease and/or presence of any new lesions, which were evaluated as per local guidelines by the clinician and were collected in the electronic case report form (e-CRF). Kaplan-Meier method was used.
At 6 months from the date of palbociclib initiation in routine clinical practice
Percentage of Participants Who Were Progression Free at 12 Months Post Palbociclib Initiation
大体时间:At 12 months from the date of palbociclib initiation in routine clinical practice
Percentage of participants who were progression free was defined as percentage of participants who were alive and for whom no progression of disease was reported. Progression of disease was defined as an increase in visible disease and/or presence of any new lesions, which were evaluated as per local guidelines by the clinician and were collected in the e-CRF. Kaplan-Meier method was used.
At 12 months from the date of palbociclib initiation in routine clinical practice
Percentage of Participants Who Were Progression Free at 18 Months Post Palbociclib Initiation
大体时间:At 18 months from the date of palbociclib initiation in routine clinical practice
Percentage of participants who were progression free was defined as percentage of participants who were alive and for whom no progression of disease was reported. Progression of disease was defined as an increase in visible disease and/or presence of any new lesions, which were evaluated as per local guidelines by the clinician and were collected in the e-CRF. Kaplan-Meier method was used.
At 18 months from the date of palbociclib initiation in routine clinical practice
Percentage of Participants Who Were Progression Free at 24 Months Post Palbociclib Initiation
大体时间:At 24 months from the date of palbociclib initiation in routine clinical practice
Percentage of participants who were progression free was defined as percentage of participants who were alive and for whom no progression of disease was reported. Progression of disease was defined as an increase in visible disease and/or presence of any new lesions, which were evaluated as per local guidelines by the clinician and were collected in the e-CRF. Kaplan-Meier method was used.
At 24 months from the date of palbociclib initiation in routine clinical practice
Percentage of Participants Who Were Alive at 1 Year Post Palbociclib Initiation
大体时间:At 1 year from the date of palbociclib initiation in routine clinical practice
Percentage of participants who were alive at 1 year post palbociclib initiation were reported in this outcome measure.
At 1 year from the date of palbociclib initiation in routine clinical practice
Percentage of Participants Who Were Alive at 2 Years Post Palbociclib Initiation
大体时间:At 2 year from the date of palbociclib initiation in routine clinical practice
Percentage of participants who were alive at 2 years post palbociclib initiation were reported in this outcome measure.
At 2 year from the date of palbociclib initiation in routine clinical practice

次要结果测量

结果测量
措施说明
大体时间
Objective Response Rate (ORR)
大体时间:From initiation of palbociclib treatment until end of follow up, or until participant's withdrawal from the study or death, whichever came first (maximum up to 24 months)
ORR was defined as the percentage of participants with an overall tumor response of complete response (CR) or partial response (PR) or stable disease. Complete response was defined as complete reduction of all visible disease; partial response was defined as partial reduction in size of visible disease in some or all areas without any areas of increase in visible disease; stable disease was defined as no change in overall size of visible disease, also including cases where some lesions increased in size and some lesions decreased in size. The responses were evaluated as per local guidelines by the clinician and were collected in the e-CRF.
From initiation of palbociclib treatment until end of follow up, or until participant's withdrawal from the study or death, whichever came first (maximum up to 24 months)
Time From Initial Breast Cancer Diagnosis to Recurrence of Breast Cancer
大体时间:At baseline (prior to initiation of palbociclib treatment)
Data for time from initial breast cancer diagnosis to recurrence of breast cancer was collected at baseline from participants medical records.
At baseline (prior to initiation of palbociclib treatment)
Number of Participants According to Stage of Breast Cancer
大体时间:At baseline (prior to initiation of palbociclib treatment)
Breast cancer stages included Stage I,IIA,IIB,IIIA,IIIB,IIIC as determined using Tumor Node Metastasis (TNM) classification system. Stage I: cancer is small and only in breast tissue or may be found in lymph nodes close to breast. Stage 2: there is cancer in breast or nearby lymph nodes or both. Stage IIA: no tumor found in breast, but cancer is found in one to three axillary lymph nodes, tumor measures 2 centimeter (cm) or smaller; IIB: tumor is larger than 2 cm. Stage 3: cancer is found in lymph nodes close to breast, skin of breast, or chest wall. Stage IIIA: any size tumor; spread to four to nine lymph nodes. Stage IIIB: any size tumor and has spread to chest wall and/or skin of breast and may have spread to up to nine axilliary lymph nodes or near breastbone. Stage IIIC: any size tumor and may have spread to chest wall or skin of breast and ten or more lymph nodes. Higher stage indicates more advanced disease.
At baseline (prior to initiation of palbociclib treatment)
Number of Participants According to Node Status
大体时间:At baseline (prior to initiation of palbociclib treatment)
Number of participants classified according to node status were reported in this outcome measure. Node status included: N0, N1, N2, N3, NX. N0: there is no cancer in nearby lymph nodes, N1, N2 and N3: number and location of lymph nodes that contained cancer and NX: cancer is nearby lymph nodes cannot be measured.
At baseline (prior to initiation of palbociclib treatment)
Number of Participants According to Menopausal Status
大体时间:At baseline (prior to initiation of palbociclib treatment)
Number of participants classified according to menopausal status were reported in this outcome measure. Menopausal status included: pre-menopausal and post-menopausal.
At baseline (prior to initiation of palbociclib treatment)
Number of Participants According to Prescribed Palbociclib Combination
大体时间:At baseline (prior to initiation of palbociclib treatment)
Number of participants classified according to palbociclib combination prescribed (palbociclib plus letrozole/aromatase inhibitor and palbociclib plus fulvestrant) at palbociclib treatment initiation were reported in this outcome measure.
At baseline (prior to initiation of palbociclib treatment)
Number of Participants According to Sites of Metastases
大体时间:At baseline (prior to initiation of palbociclib treatment)
Number of participants classified according to sites of metastases (visceral and non-visceral) were reported in this outcome measure.
At baseline (prior to initiation of palbociclib treatment)
Number of Participants According to Metastatic Status
大体时间:At baseline (prior to initiation of palbociclib treatment)
Number of participants classified according to metastatic status (denovo advanced BC and recurrent/relapse advanced BC) were reported in this outcome measure.
At baseline (prior to initiation of palbociclib treatment)
Mean Weight of the Participants
大体时间:At baseline (prior to initiation of palbociclib treatment)
At baseline (prior to initiation of palbociclib treatment)
Number of Participants Categorized According to Family History of Breast Cancer
大体时间:At baseline (prior to initiation of palbociclib treatment)
Number of participants categorized according to family history of breast cancer (Yes/No) were reported in this outcome measure.
At baseline (prior to initiation of palbociclib treatment)
Number of Participants Categorized According to Treatment Schedule
大体时间:From initiation of palbociclib treatment until end of follow up, or until participant's withdrawal from the study or death, whichever came first (maximum up to 24 months)
Number of participants categorized according to treatment schedule of 3 weeks on, 1 week off (Yes) were reported in this outcome measure.
From initiation of palbociclib treatment until end of follow up, or until participant's withdrawal from the study or death, whichever came first (maximum up to 24 months)
Number of Participants Categorized According to Palbociclib Dose
大体时间:From initiation of palbociclib treatment until end of follow up, or until participant's withdrawal from the study or death, whichever came first (maximum up to 24 months)
Number of participants categorized according to palbociclib dose (75 milligram [mg], 100 mg and 125 mg) were reported in this outcome measure.
From initiation of palbociclib treatment until end of follow up, or until participant's withdrawal from the study or death, whichever came first (maximum up to 24 months)
Number of Participants Categorized According to Accompanying Endocrine Treatments
大体时间:From initiation of palbociclib treatment until end of follow up, or until participant's withdrawal from the study or death, whichever came first (maximum up to 24 months)
Number of participants categorized according to accompanying endocrine treatments were reported in this outcome measure. Accompanying endocrine treatments included: tamoxifen/NOLVADEX , toremifene / FARESTON, raloxifene / EVISTA, anastrozole / ARIMIDEX, letrozole / FEMARA, exemestane / AROMASIN, fulvestrant / FASLODEX, goserlin acetate / Zoaldex, leuprorelin /Lupron, triptorelin / Decapeptyl, degarelix / Firmagon. One participant may have received more than one endocrine treatment accompanying palbociclib treatment.
From initiation of palbociclib treatment until end of follow up, or until participant's withdrawal from the study or death, whichever came first (maximum up to 24 months)
Number of Participants With Dose Interruption
大体时间:From initiation of palbociclib treatment until end of follow up, or until participant's withdrawal from the study or death, whichever came first (maximum up to 24 months)
Number of participants with palbociclib dose interruption were reported in this outcome measure.
From initiation of palbociclib treatment until end of follow up, or until participant's withdrawal from the study or death, whichever came first (maximum up to 24 months)
Number of Participants With Dose Delays
大体时间:From initiation of palbociclib treatment until end of follow up, or until participant's withdrawal from the study or death, whichever came first (maximum up to 24 months)
Number of participants with dose delays were reported in this outcome measure.
From initiation of palbociclib treatment until end of follow up, or until participant's withdrawal from the study or death, whichever came first (maximum up to 24 months)
Number of Participants Who Discontinued Palbociclib Treatment
大体时间:From initiation of palbociclib treatment until end of follow up, or until participant's withdrawal from the study or death, whichever came first (maximum up to 24 months)
Number of participants who discontinued palbociclib treatment were reported in this outcome measure.
From initiation of palbociclib treatment until end of follow up, or until participant's withdrawal from the study or death, whichever came first (maximum up to 24 months)
Duration of Palbociclib Treatment
大体时间:From initiation of palbociclib treatment until end of follow up, or until participant's withdrawal from the study or death, whichever came first (maximum up to 24 months)
Duration of palbociclib treatment was defined as time (in days) from first to last day in palbociclib treatment.
From initiation of palbociclib treatment until end of follow up, or until participant's withdrawal from the study or death, whichever came first (maximum up to 24 months)
Number of Participants According to Supportive Therapies Received During Palbociclib Combination Treatment
大体时间:From initiation of palbociclib treatment until end of follow up, or until participant's withdrawal from the study or death, whichever came first (maximum up to 24 months)
Number of participants according to supportive therapies received during palbociclib combination treatment were reported in this outcome measure. Supportive therapies included: zoledronic acid, calcium supplement, alfacalcidol, letrozole, vitamin D, gabapentin, tramadol, denosumab, granisetron, morphine, filgrastim, metoclopramide, dexamethasone, domperidone, duloxetine, fulvestrant, ondansetron, prednisolone, citalopram, itopride, oxycodone, pregabalin, sertraline. One participant may have received more than one supportive therapy.
From initiation of palbociclib treatment until end of follow up, or until participant's withdrawal from the study or death, whichever came first (maximum up to 24 months)
Number of Participants Categorized According to Adjuvant Therapies
大体时间:At baseline (prior to initiation of palbociclib treatment)
Number of participants categorized according to adjuvant therapies were reported in this outcome measure. Adjuvant therapies included: adjuvant chemotherapy, adjuvant hormonal therapy, experimental adjuvant therapy, neoadjuvant chemotherapy, neoadjuvant hormonal therapy, radiotherapy and surgery. One participant may have received more than one type of adjuvant therapy.
At baseline (prior to initiation of palbociclib treatment)
Time Between Start of Palbociclib Treatment and End of Adjuvant Therapy for Early/Locally Advanced Breast Cancer
大体时间:At baseline (prior to initiation of palbociclib treatment)
Time between start of palbociclib treatment and end of therapy for early/locally advanced BC was calculated as date of initiation of palbociclib treatment - date of end of therapy for early/locally advanced therapy. Time between start of palbociclib treatment and end of adjuvant therapy for early/locally advanced breast cancer was collected at baseline from participant's medical records.
At baseline (prior to initiation of palbociclib treatment)
Number of Participants According to Therapies Received Before Palbociclib Treatment
大体时间:At baseline (prior to initiation of palbociclib treatment)
Number of participants according to therapies received before palbociclib treatment were reported in this outcome measure. Therapies included: MBC chemotherapy, MBC hormonal therapy (other than Palbociclib combination), combination therapy, other therapy, radiotherapy and surgery. One participant may have received more than one type of therapy. Therapies for which non-zero data were available have been reported below.
At baseline (prior to initiation of palbociclib treatment)
Duration of Therapy for Treatment Received Before Palbociclib Treatment
大体时间:At baseline (prior to initiation of palbociclib treatment)
At baseline (prior to initiation of palbociclib treatment)
Number of Participants According to First Subsequent Therapy Received After Palbociclib Treatment Discontinuation
大体时间:From palbociclib treatment discontinuation until end of follow up, or until participant's withdrawal from the study or death, whichever came first (maximum up to 24 months)
Number of participants according to first subsequent therapy received after palbociclib treatment discontinuation were reported in this outcome measure. Subsequent therapies included systemic therapy, radiotherapy, surgery and other therapy. Subsequent therapies for which non-zero data were available have been reported below.
From palbociclib treatment discontinuation until end of follow up, or until participant's withdrawal from the study or death, whichever came first (maximum up to 24 months)
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Scale Scores
大体时间:At 6, 12, 18 and 24 months post palbociclib treatment initiation
EORTC QLQ-30 included five functional scales (physical functioning, role, emotional, cognitive and social functioning), nine symptom scales (fatigue, nausea or vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea and financial difficulties, and a global health status scale (GHS). The GHS/QoL scale ranged from 1=very poor to 7=excellent. All other items ranged from 1=not at all to 4=very much. A linear transformation was applied to the raw scores so that all transformed scores lie between 0 to 100, with 0 being the worst and 100 being the best for GHS and functional scales, and 0 being the best and 100 being the worst for symptom scales.
At 6, 12, 18 and 24 months post palbociclib treatment initiation

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

调查人员

  • 研究主任:Pfizer CT.gov Call Center、Pfizer

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2021年7月15日

初级完成 (实际的)

2025年4月29日

研究完成 (实际的)

2025年4月29日

研究注册日期

首次提交

2021年6月8日

首先提交符合 QC 标准的

2021年6月23日

首次发布 (实际的)

2021年6月24日

研究记录更新

最后更新发布 (实际的)

2026年6月10日

上次提交的符合 QC 标准的更新

2026年6月9日

最后验证

2026年6月1日

更多信息

与本研究相关的术语

其他研究编号

  • A5481150
  • PRECIOUS (其他标识符:Alias Study Number)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

辉瑞将提供对个人去识别参与者数据和相关研究文件(例如 协议、统计分析计划 (SAP)、临床研究报告 (CSR))根据合格研究人员的要求,并遵守某些标准、条件和例外情况。 有关辉瑞数据共享标准和请求访问流程的更多详细信息,请访问:https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests。

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅